General information, events and/or links.



The OncoGenomics Group

Group information, relevant EV research and instrumentation

Group name

The OncoGenomics Group/Translational Studies in Solid Tumors (TSST)





Department  of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet

Link to homepage:   and






Steering group member

Elin H. Kure


Deputy representative

Åslaug Helland


Group members

Astrid Marie Dalsgaard


Ann Rita Halvorsen


Vandana Sandhu


Martina Landschoof Skrede



Scientific background/relevant EV research:

Our group focuses on translational studies on solid tumors, with a special interest in pancreatic cancers, lung cancers, ovary cancers and colorectal cancers. We do whole genome analyses on patient material, aiming at identifying predictive and prognostic biomarkers. We are analyzing mRNA, miRNA, DNA, methylation, glycosylation, mutations and proteins. By increasing the understanding of the underlying biology of tumor development, we aim at improving cancer patient care. Several of our projects include material from patients included in clinical studies, and we have clinical and follow-up data from all patients. The group has three research project groups, with a total of 17 members and four associate members. Eight of these 17 are MDs. We are three researchers, two post docs, nine PhD-students, one study nurse and two engineers.



The ultimate goal is to personalize cancer treatment, and improve prognosis.

  • Identification of  biomarkers in blood samples, for diagnostics, follow-up and prognostication
  • Identification of tumor biomarkers for prediction of therapy response and for prognostication


Molecular profiling of lung cancer and head and neck cancer

In search for improved means of early detection, Dr. Åslaug Helland’s group have sampled blood samples from lung cancer patients. MiRNA detection, either in exosomes or free in serum, is part of the lung cancer projects. In head and neck cancer, they are in the process of starting sampling of sputum, for the same purposes.


Circulating biomarkers in plasma of pancreatic cancer patients

The goal is to evaluate EV-cargo as diagnostic and/or prognostic biomarkers in plasma of patients with periampullary adenocarcinomas. Our research seeks to highlight the translational value of tumor derived exosomes as functional rather than surrogate biomarkers. As such, it represents a new field of non-invasive biomarker discovery that could be of great significance to cancer care. We want to address the following main question: Are miRNAs and proteins in plasma circulating exosome potential biomarkers for early detection and metastatic potential of pancreatic cancer?


External collaborators: David Lyden's group, Cornell University, New York, USA

OUH collaborators:

  • KJ Labori, IP Gladhaug and T Buanes, Department of Hepato-Pancreato-Biliary Surgery 
  • O Dajani, Department of Oncology
  • CS Verbeke, Department of Pathology
  • V Kristensen Department of Cancer Genetics, KRF/ University of Oslo and AHUS



Instrumentation (relevant for EV research):

  • Agilent microarray Technology – gene expression studies (miRNA, mRNA, DNA)
  • Qiacube – automated isolation of RNA, DNA, protein
  • BioRobot Universal – automated medium to high-throughput isolation of RNA and DNA
  • QIAsymphony SP/AS - automated isolation of RNA, DNA, protein and assay setup
  • 7900HT Fast Real-Time PCR System
  • Nanodrop ND-1000 and 3300 – quantification of nucleic acids and proteins
  • Bioanalyzer – quality control of mRNA, miRNA , DNA and proteins
  • Flow Cytometry
  • Luminex – multiplex analysis of proteins
  • MiSeq – Sequencing machine
  • Ion Torrent – Sequencing machine



August 21st, 2015

Previous page: Network groups  Next page: The Blood Cell Research Group